- Trial phase
- Phase 1 completed; Phase 2b planned
- Time to market
- If Phase 2b initiates in 2027 and proceeds smoothly, a potential approval would likely be several years away (estimated 2029-2031), assuming positive data across Phase 2b and Phase 3 trials.
- Why 3/10
- No hard, dated binary catalyst is scheduled in the next ~12 months. PN-881 has completed Phase 1, and a comprehensive Phase 2b program for psoriasis is planned but not yet initiated with no specific start date announced. The drug is an early-stage pipeline asset at a company with two already-approved, revenue-generating products, so it is not a near-term value driver.
Watch for the initiation of the Phase 2b psoriasis program, which the company has guided as planned. Positive Phase 1 safety/tolerability data could support a rapid move into Phase 2b. As a wholly-owned asset at a now-profitable company with two approved drugs, PN-881 represents pipeline upside but is not a near-term binary catalyst.
Price Chart
Executive Summary
PN-881 is an oral peptide IL-17 antagonist being developed by Protagonist Therapeutics (NASDAQ: PTGX) for psoriasis and potentially other IL-17-mediated inflammatory diseases. It is a wholly-owned asset (not partnered), unlike the company's two approved drugs ICOTYDE (icotrokinra, partnered with J&J) and rusfertide (partnered with Takeda). PN-881 was nominated as a development candidate in November 2024, completed its Phase 1 SAD/MAD study by mid-2026, and the company has guided a comprehensive Phase 2b program for psoriasis as the next step. Preclinical data showed potency comparable to the injectable biologic bimekizumab and roughly 70-100 fold greater than secukinumab. As an early-stage pipeline asset at a now-profitable company with two revenue-generating approved products, PN-881 represents long-term pipeline upside rather than a near-term binary catalyst.
How It Works
PN-881 is an oral (pill) peptide drug that blocks the IL-17 pathway, a key driver of inflammation in psoriasis and other autoimmune diseases. It works by binding to and neutralizing IL-17 proteins (the AA, FF and AF forms) that trigger skin inflammation. Unlike current IL-17 blockers which are injections or infusions, PN-881 is designed to be taken orally as a peptide, which could be more convenient for patients.
Trial Status
PN-881 was nominated as a development candidate in November 2024. A Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study (NCT07153146) began in late 2025 and was completed by August 2026. The company has announced plans for a comprehensive Phase 2b program in psoriasis but has not yet provided a specific start date.
The Two-Sided Case
Upcoming Catalysts
- Initiation of Phase 2b clinical program for psoriasis (timing not yet specified)
- Potential presentation of Phase 1 safety/tolerability data at a medical conference
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Protagonist Therapeutics, Inc 8-K PTGX ·Originating report